Predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy

Bookmark and Share
Published: 9 Mar 2009
Views: 14337
Rating:
Save
Dr Angelo Di Leo - Sandro Pitigliani Medical Oncology Unit, Prato Hospital
A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy, Angelo Di Leo, M.D., Ph.D., head of the Sandro Pitigliani Medical Oncology Unit at the Hospital of Prato, Instituto Toscano Tumori in Italy . Speaking at San Antonio Breast Cancer Symposium 2008.